Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Dietary Intervention (Soy Soft Pretzels) for Reducing Chronic Inflammation in Obese Individuals

10. juni 2026 opdateret af: Holli Loomans-Kropp, Ohio State University Comprehensive Cancer Center

Examining the Efficacy of a Soft Soy Pretzel Intervention in Altering Chronic Inflammation and Immune Profiles in Obese Individuals

This clinical trial compares the effects of soy soft pretzels versus wheat pretzels on inflammatory markers in individuals with obesity. Obesity is a serious public health problem that can lead to chronic inflammation, which is associated with many negative health conditions and some types of cancer. Soy versus wheat pretzels may be processed by the body differently, and the components in these pretzel snacks may be helpful for reducing inflammation. Soy soft pretzels are made with soybeans, which contain many natural chemicals that may be beneficial to human health, such as isoflavones. Existing research has suggested that diets enriched with isoflavones may help reduce inflammation. However, the relationship between soy-rich diets and the immune systems of obese individuals is not well understood. This trial may help researchers determine whether soy soft pretzels are useful for lowering markers of chronic inflammation, compared to wheat pretzels, in individuals with obesity.

Studieoversigt

Detaljeret beskrivelse

PRIMARY OBJECTIVES:

I. Assess alterations in chronic inflammatory markers with soft soy pretzel (SSP) intervention among individuals with obesity.

II. Define immune cell populations in obese individuals with SSP intervention.

OUTLINE: Patients with a body mass index (BMI) ≥ 30 and C-reactive protein (CRP) ≥ 0.06 mg/dL are randomized to 1 of 2 arms. Patients with BMI 18.5-24.9 and detectable CRP are assigned to arm III.

ARM I: Patients consume 8 SSP bites twice daily (BID) for 14 days (days 1-14) and then begin a two-week washout period (days 15-28). Following the washout period, patients consume wheat pretzel (WP) bites BID for 14 days (days 28-42). Patients also undergo collection of blood and urine samples on study.

ARM II: Patients consume 8 WP bites BID for 14 days (days 1-14) and then begin a two-week washout period (days 15-28). Following the washout period, patients consume SSP bites BID for 14 days (days 28-42). Patients also undergo collection of blood and urine samples on study.

ARM III: Assigned to Arm I.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

30

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Ohio
      • Columbus, Ohio, Forenede Stater, 43210
        • Ohio State University Comprehensive Cancer Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen

Tager imod sunde frivillige

Ja

Beskrivelse

Inclusion Criteria:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures, lifestyle considerations, and availability for the duration of the study
  • Males sex
  • 18 and 49 years of age
  • Height and weight or calculated BMI for:

    • Obese participants must be ≥ 30 kg/m^2
    • Non-obese (healthy) participants must be between 18.5 and 24.9 kg/m^2

Exclusion Criteria:

  • Inability to comply with all study procedures, lifestyle considerations, and availability for the duration of the study
  • Known allergy or intolerance to soy, wheat, or any other ingredients in study intervention
  • Current or prior history of type 2 diabetes mellitus as defined by International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) E11
  • Current or prior history of cancer (excluding non-melanoma skin cancers)
  • History of blood clotting disorders or adverse events relating to blood draws
  • Use of antibiotic regime lasting longer than one week within the last six months
  • Current enrollment in other research studies for weight loss
  • Actively trying to lose weight and/or use of medications for weight loss within the last three months
  • Strict veganism (no consumption of animal, fish, or egg products)
  • Heavy alcohol consumption (defined as consumption of > 14 drinks/week on average)
  • Current or prior history of any condition that causes altered immunity such as chronic inflammatory disease, autoimmune disorders, cancer, anemia, and blood dyscrasias
  • Regular usage of inflammation lowering medications which include but not limited to nonsteroidal anti-inflammatory drugs such as aspirin, ibuprofen, and naproxen, or anti-pyretic medications such as acetaminophen

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Forebyggelse
  • Tildeling: Randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Arm I (SSP, WP)
Patients consume 8 SSP bites BID for 14 days (days 1-14) and then begin a two-week washout period (days 15-28). Following the washout period, patients consume WP bites BID for 14 days (days 28-42). Patients also undergo collection of blood and urine samples on study.
Hjælpestudier
Gennemgå indsamling af blod- og urinprøver
Andre navne:
  • Biologisk prøvesamling
  • Bioprøve indsamlet
  • Prøvesamling
  • Prøvekollektion
Consume SSPs
Andre navne:
  • Kostændringer
  • intervention, diæt
  • Ernæringsintervention
  • Ernæringsinterventioner
  • Ernæringsmæssige interventioner
Consume WPs
Andre navne:
  • Kostændringer
  • intervention, diæt
  • Ernæringsintervention
  • Ernæringsinterventioner
  • Ernæringsmæssige interventioner
Eksperimentel: Arm II (WP, SSP)
Patients consume 8 WP bites BID for 14 days (days 1-14) and then begin a two-week washout period (days 15-28). Following the washout period, patients consume SSP bites BID for 14 days (days 28-42). Patients also undergo collection of blood and urine samples on study.
Hjælpestudier
Gennemgå indsamling af blod- og urinprøver
Andre navne:
  • Biologisk prøvesamling
  • Bioprøve indsamlet
  • Prøvesamling
  • Prøvekollektion
Consume SSPs
Andre navne:
  • Kostændringer
  • intervention, diæt
  • Ernæringsintervention
  • Ernæringsinterventioner
  • Ernæringsmæssige interventioner
Consume WPs
Andre navne:
  • Kostændringer
  • intervention, diæt
  • Ernæringsintervention
  • Ernæringsinterventioner
  • Ernæringsmæssige interventioner
Eksperimentel: Arm III (WP, SSP)
Patients receive intervention as in Arm I. Patients also undergo collection of blood and urine samples on study.
Hjælpestudier
Gennemgå indsamling af blod- og urinprøver
Andre navne:
  • Biologisk prøvesamling
  • Bioprøve indsamlet
  • Prøvesamling
  • Prøvekollektion
Consume SSPs
Andre navne:
  • Kostændringer
  • intervention, diæt
  • Ernæringsintervention
  • Ernæringsinterventioner
  • Ernæringsmæssige interventioner
Consume WPs
Andre navne:
  • Kostændringer
  • intervention, diæt
  • Ernæringsintervention
  • Ernæringsinterventioner
  • Ernæringsmæssige interventioner

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Differences in chronic inflammatory biomarkers
Tidsramme: Up to 42 days
Will be compared between interventions using a repeated measures analysis of variance and between obese and normal body mass index groups. Inflammatory biomarker concentrations will be determined by comparing signal intensity of each well to a generated standard curve and averaged to make a single data point per biomarker per individual. Biomarker concentrations will be transformed to prevent heteroskedasticity. Depending on the underlying distribution of the data, Student's t-test or Mann-Whitney U will be used to compare individual biomarker expression values, using Bonferroni correction for multiple comparisons. Immunophenotyping will be analyzed using log-transformed cell counts and comparisons of defined populations between groups, with statistical significance corrected for multiple comparisons.
Up to 42 days
Differences in percentages of immune cell populations
Tidsramme: Up to 42 days
Will be compared between interventions using a repeated measures analysis of variance and between obese and normal body mass index groups. Immune cell population analyses will be visualized using clustering and t-stochastic neighbor embedding plots.
Up to 42 days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Holli Loomans-Kropp, PhD, MPH, Ohio State University Comprehensive Cancer Center

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. juni 2025

Primær færdiggørelse (Anslået)

30. september 2026

Studieafslutning (Anslået)

31. december 2026

Datoer for studieregistrering

Først indsendt

10. juni 2026

Først indsendt, der opfyldte QC-kriterier

10. juni 2026

Først opslået (Faktiske)

16. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. juni 2026

Sidst verificeret

1. juni 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Kolorektalt karcinom

Kliniske forsøg med Spørgeskemaadministration

Abonner